You’re looking at a stock with better vitals than the market’s giving it credit for.
The price hasn’t caught up, but you can.
If you want a setup where fundamentals lead, and the market eventually follows, you’re standing right in it.
New Era (Sponsored)
Most people stick to the basics because old platforms made it complicated.
Not anymore.
Today’s brokers offer fast execution, flexible order types, fractional trading, and extended hours so you can act when it matters, not after.
If you're ready for more control and more ways to grow, start here.
COMPARE THE TOP PLATFORMS
Why This Stock’s Heartbeat Is Stronger Than Wall Street Thinks
You’re looking at a stock that just picked up real momentum.
Medtronic PLC (NYSE: MDT) is stepping into a stronger phase with upgraded expectations and a regulatory win that actually shifts its trajectory.
The earnings outlook has been tightening, the product pipeline just scored a major boost, and the share price still isn’t fully reflecting the shift.
MDT has been climbing steadily, and you’re now staring at a setup that feels more like a company gearing up than one relying on its legacy.
Action: Pick up shares while they’re hovering near $101–102, because this is the part of the chart where momentum usually sneaks in before headlines catch up.
Treat this as your “early check-in” before Wall Street finally names the condition.
High Potential (Sponsored)
Every market cycle produces a select group of companies that drastically outperform the rest.
The latest screening has pinpointed the 5 Stocks Set to Double, each showing rare traits linked to early stage momentum.
These names carry the same type of indicators that have historically appeared ahead of strong rallies.
Earlier reports featured stocks that delivered +175%, +498%, and +673%.
Get the Free 5 Stocks Set to Double Report.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
The Math Behind the Mispricing
If you look at MTD and feel like the price is half awake, you’re reading it right.
Momentum is leaning upward, the business is sharpening its edge, and the gap between performance and pricing is wide enough for you to step into if you’re paying attention.
Here’s what you should be noticing:
Valuation Lag: MTD is cruising slower than its actual progress, giving you a clean look at a pricing mismatch with room to exploit before the market corrects itself.
Growth Setup: Forward expectations are firming up ahead of the price action, pointing to upside that the market hasn’t fully priced in.
Range Support: The stock keeps defending its range with confidence, showing steady buyer interest and reinforcing the underlying strength behind the story.
Trend Alignment: The fundamentals and the trend are finally speaking the same language, creating one of those rare windows where business improvement and momentum are actually moving together.
The disconnect isn’t subtle, and it’s not closing yet.
As long as the operational footing and the trend keep reinforcing one another, this is the kind of pricing gap you don’t gloss over.
Action: If MDT dips into the $96–98 zone, treat it like a clearance rack find. Set your sights on the $110–115 range, because that’s where pricing and reality tend to stop arguing.
Clear Signals (Sponsored)
When he appeared on live TV and made a bold prediction, the hosts couldn’t believe it.
But when the market moved exactly as he said, people started paying attention.
His secret? A simple trading indicator that shows clear buy and sell moments — without guesswork or emotion.
He’s used it for 30 years.
It guided him through every kind of market.
And now, he’s sharing it for free.
This same indicator has flashed again… and what it’s showing might surprise you.
[Get the free indicator here]
Why MDT Still Isn’t Getting Full Credit
Medtronic is showing stronger fundamentals than the stock price reflects.
Earnings estimates are trending upward, operational discipline is tightening, and the company is moving past its softer stretches.
Yet the stock is acting cautiously, leaving a gap between performance and pricing that hasn’t closed.
Momentum Building: MDT’s results are firming, with forward expectations hinting at continued stability and growth. This signals that the business is consolidating its momentum and setting up for a smoother trajectory.
Price vs Performance Disconnect: The stock remains conservative while the underlying business accelerates, creating a disconnect that rarely sticks around once the trend becomes obvious.
Execution Strength: Cost management, execution, and strategic initiatives are hitting their marks, providing solid support even before the market fully recognizes the progress.
Market Attention Delay: Attention hasn’t fully shifted to MDT’s improving story, giving you room to step in before the market catches up.
All these points together show that MDT is building a stronger foundation than the price suggests, giving you a chance to position yourself while the stock lags.
Action: Add a small booster position if the next earnings revision bumps upward... that’s your green light that the market is waking up.
Cap your risk with a soft floor around $92, just in case the story hits an unexpected plot twist.
Don’t Let These Undervalued Stocks Slip Through Your Fingers!
We now send our favorite value picks via text, too, so you’ll get the same actionable news without having to open your inbox.
Peer Check: Where MDT Actually Stands
Medtronic is moving with a steadier footing than many of its peers, showing cleaner execution and more consistent operational progress.
While some competitors are still juggling uneven results, MDT is holding its ground and pulling ahead.
You see them steadily gaining attention in the market, demonstrating resilience across multiple product lines, and proving that disciplined strategy and focused execution create tangible advantages over less consistent peers.
Forward Momentum: Results are coming in consistently, giving MDT a clear performance lead over peers.
Market Misstep: The stock trades more conservatively than companies showing weaker progress, making the upside potential more apparent.
Strong Fundamentals: Execution and cost discipline are outperforming the group, reinforcing the stock’s relative strength.
Attention Delay: The trend in MDT shares is firming while peers show softer movement, highlighting where strength is really happening.
MDT is pulling ahead of the pack, and the market still hasn’t caught up to the advantage it’s building.
Action: Shift a slice of your medtech allocation toward MDT whenever a peer stumbles; strength deserves more weight than excuses.
Aim to let MDT take 20–30% of your healthcare sleeve so the overachiever finally gets paid like one.
Peer Check: Where MDT Stands
Medtronic is gaining traction while many of its peers in medtech and adjacent categories struggle with uneven growth and volatile results.
You can see the company’s consistent execution and operational improvements, giving it a clearer footing, letting it stand out in a crowded and unpredictable landscape.
Improving Footing: MDT is moving steadily ahead while competitors continue to wobble, showing you that disciplined execution and strong fundamentals make a real difference in performance.
Execution Edge: Operational control, backlog stability, and consistent project delivery reinforce MDT’s relative strength compared with peers still finding their rhythm.
Momentum Lead: Renewed product launches and earnings consistency are helping MDT pull ahead while other names are still reacting to shifting narratives, giving you a visible performance advantage.
Taken together, these trends put MDT in a class of its own, delivering consistent performance while much of the sector struggles to stabilize.
Action: Hold MDT through competitor noise, because this is the kid in class who keeps handing in assignments early.
If volatility spikes in the sector, use it to top up lightly. MDT historically outruns weaker hands when panic hits.
Poll: A $20 bill appears in your pocket. What now?
Sector Tailwinds and What’s Steering the Shift
Robotic surgery and minimally invasive procedures are gaining momentum across the globe, reshaping how you and surgical teams approach complex operations.
The urology robotics market alone is projected to grow steadily, and Medtronic is perfectly positioned to capture this expansion with its Hugo RAS system and integrated surgical offerings.
Global Adoption: You can see MDT’s solutions being used in tens of thousands of procedures worldwide, proving that hospitals are embracing robotic platforms for better outcomes and efficiency.
Expanding Use Cases: From urology to gynecology and general surgery, the applications of minimally invasive and robotic-assisted care are broadening, giving you multiple avenues to track growth.
Multi-Modality Dominance: Medtronic is uniquely positioned with solutions across open, laparoscopic, and robotic-assisted surgery, letting you follow its leadership across every level of surgical complexity.
These trends confirm strong sector momentum, positioning Medtronic as a key player driving the move toward efficient, tech-enabled healthcare solutions.
Action: If the Hugo system gets another clearance or adoption update, scale in. Robotics momentum usually lifts MDT like a backstage pulley.
Keep this portion of your position long-term, because surgical robots don’t go out of style… unlike half the Nasdaq.
The Trade-Off: Balancing Stability and Opportunity
Medtronic is delivering steady performance, but there are still bumps to navigate.
Rising project costs and timing shifts could create some near-term fluctuations, yet the stock’s valuation has already priced in much of that caution.
Execution remains solid, margins are holding, and revenue visibility is improving, giving you a stable foundation to work with while the broader story unfolds.
Backlog is stabilizing, contracts are progressing as expected, and operational discipline continues to reinforce the company’s position.
Cost Pressure: Project expenses and timing changes could impact near-term results, but strong operational control keeps the downside manageable and prevents surprises from derailing progress.
Execution Risk: Operations, project delivery, and resource allocation are on track, ensuring that the company continues to meet expectations and maintain momentum despite external pressures.
Downside Cushion: The current valuation reflects caution and risk, providing a buffer while fundamentals continue to strengthen and trends begin to align more clearly.
Upside Bias: Improving project flow, consistent execution, and backlog visibility creates a runway for potential gains as the market slowly recognizes the company’s stronger performance.
Altogether, MDT balances steady execution with growth potential, giving you a clear path to benefit from gains while navigating market fluctuations safely.
Action: Let your position breathe, but keep a 12–15% trailing stop, giving MDT room to work without letting it redecorate your downside.
When margins expand even slightly, bump your stake; this stock rewards discipline, not impulse.
Final Word: MDT’s Steady Value Play
Earnings are solid, margins are holding, and project flow is improving, giving you a clear picture of a business that’s moving in the right direction with growing momentum.
Medtronic is trading below what its operational strength deserves, creating a rare chance for you to align with a company that delivers reliability, steady progress, and emerging upside at the same time.
The combination of stable execution, revenue visibility, and disciplined cost management sets a foundation that supports both steady growth and significant upside potential.
As the market gradually recognizes these fundamentals, the stock is positioned to reflect the true strength already in place and the broader strategic initiatives driving long-term performance.
This is not about chasing hype or short-term swings; it is about getting in on a story that’s already unfolding clearly in the numbers and operational trends.
Setup Scorecard
Entry Window: MDT is holding gains with strengthening near-term catalysts and a stable multi-quarter setup, giving you a clear point to engage with the story.
Catalyst Watch: Keep an eye on the rollout of the Hugo system, updates on expanded indications, and how the growing sensor ecosystem is driving adoption.
Upside Setup: Strong earnings signals, regulatory wins, and robotics optionality continue to apply upward pressure, showing you where the stock could head next.
Downside Cushion: Valuation already factors in caution, and consistent fundamentals and execution give you a solid floor under the stock.
What Moves It Now: Follow the Hugo deployment curve, sensor adoption trends, and forward earnings revisions to track where momentum is likely to build next.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you'd like us to dig into.
Best Regards,
—Noah Zelvis
Undervalued Edge
